The government says regulatory requirements for generic biological therapies will have to be tailored to the treatment in question.
Advertisement
The Scientist
Most Recent
For the first time, a plant-produced antibody gets the green light for clinical trials in the United Kingdom.
A highly virulent strain of E. coli has caused an unusually high number of severe kidney disease
Follow The Scientist
Stay Connected with The Scientist
-
The Scientist Magazine
-
The Scientist Careers
-
Neuroscience Research Techniques
-
Genetic Research Techniques
-
Cell Culture Techniques
-
Microbiology and Immunology
-
Cancer Research and Technology
Current Issue
